Simple Summary Despite an initial response to therapy, many lung cancer patients
inevitably develop resistance to therapy leading to decreased duration of response and …

Tetracyclines are a group of antibiotics whose first representative was discovered over 70
years ago. Since then, they have been of great interest in dermatology. In addition to their …

Background and objective Colon cancer is occurring at an increasing rate and ginger
(Zingiber officinale), as a commonly used herbal medicine, has been suggested as a …

Background Epidermal growth factor receptor-tyrosinase kinase inhibitor (EGFR-TKI)
resistance is the major obstacle in the treatment of lung adenocarcinoma (LUAD) patients …

The rising global burden of cancer has driven considerable efforts into the research and
development of effective anti-cancer agents. Fortunately, with impressive advances in …

Background Lung adenocarcinoma (LUAD) is the most common pathological type of lung
cancer, with high incidence and mortality. To improve the curative effect and prolong the …

Epidermal growth factor receptor (EGFR) mutations are the molecular driver of a subset of
non-small cell lung cancers (NSCLC); tumors that harbor these mutations are often …

Patients with non‑small cell lung cancer (NSCLC) treated with EGFR‑tyrosine kinase
inhibitors (TKIs) ultimately develop drug resistance and metastasis. Therefore, there is a …

Karyopherin α2 (KPNA2) was reported to be overexpressed and have unfavorable
prognostic effects in many malignancies including hepatocellular carcinoma (HCC) …

This study aims to identify FDA-approved drugs that can target the kappa-opioid receptor
(KOR) for the treatment of demyelinating diseases. Demyelinating diseases are …